199730 · KOSDAQ · ₩199730 · 바이오인프라
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−70.5% from the high
₩593Today: ₩1,560 – ₩1,782₩5,420
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
BioInfra (바이오인프라, KRX: 199730) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean contract research organization founded in 2007 that provides outsourced clinical and laboratory services to pharmaceutical companies. Its shares closed at ₩1,601 on Oct 27, 2026, down 1.17% on the day, giving it a market value of ₩7.8B.
The company is a Korean contract research organization founded in 2007 that provides outsourced clinical and laboratory services to pharmaceutical companies. Its main services include bioequivalence testing for generic drugs, Phase I clinical trials for improved new drugs, regulatory clinical trials and later-stage clinical studies, immunoassay analysis of polymer biopharmaceuticals, and quality testing of finished drugs. Its business is conducted from its Yongin headquarters and Seoul branch, and it serves drug developers on a business-to-business basis.
Written by AI from the company's latest annual report.
High impactPredicted impact: High· Actual: +0.2% vs sector, volume 17.0× normal (5 trading days)
Delisting deferral lifts stock to upper limit; delisting risk is a major regulatory matter.
Predicted impact: Low· Actual: +50.9% vs sector, volume 15.6× normal (5 trading days)
Technical chart signal from a broker feed; no company news.
Titles in Korean until English translations are added.
Also known as: BioInfra / 바이오인프라 / 199730 / KRX:199730
Source: KRX statistical information